PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2023
CASE
AUTH/3757/3/23 Otsuka

Otsuka criticised for lack of transparency in PMCPA submission about earlier case (AUTH/3757/3/23)

Ex-employee alleged Otsuka withheld relevant facts and used unsigned witness statements in a 2015 PMCPA case response. Panel found breaches of Clauses…

2022
CASE
AUTH/3717/12/22 Novo Nordisk ⭐ Case of the Week

AUTH/3717/12/22: Public complaint about weight-loss media coverage – Novo Nordisk (Sunday Times interview led to breaches)

Five weight-loss media articles were complained about. Novo Nordisk was not responsible for four. One Sunday Times interview quote was ruled promotional…

2023
CASE
AUTH/3772/6/23 Daiichi-Sankyo UK

Daiichi Sankyo: Nustendi email found misleading due to implied comparator (AUTH/3772/6/23)

A third‑party promotional email for Nustendi quoted a β€œ38% LDL‑C reduction (placebo‑corrected)”. The PMCPA ruled the layout implied this was vs ezetimibe…

2023
CASE
AUTH/3785/6/23 GlaxoSmithKline

GSK breached ABPI Code over β€œTrevor trusts Trelegy” website claim (AUTH/3785/6/23)

PMCPA ruled GSK’s β€œTrevor trusts Trelegy” claim on an HCP website was ambiguous, misleading and unsubstantiated (Clauses 6.1, 6.2, 5.1). No breach…

2023
CASE
AUTH/3797/7/23 Besins Healthcare

AUTH/3797/7/23: Complainant v Besins Healthcare β€” alleged disguised promotion on Besins Hormone Academy website (No breach)

Complaint alleged Besins Hormone Academy webpages were disguised promotion. Panel found it was clearly a Besins HCP site with PI link and…

2021
CASE
CSL Vifor

CSL Vifor: Uncertified global invite to UK HCP for overseas CKD-aP meeting (difelikefalin) breached certification and mandatory info rules

CSL Vifor voluntarily admitted breaches after a global team sent a UK HCP an uncertified email invite/flyer for an overseas CKD-aP meeting…

2023
CASE
AUTH/3837/10/23 AstraZeneca ⭐ Case of the Week

AstraZeneca found in breach over HCP tweet lacking disclosure of company involvement in Speak Up for COPD campaign (AUTH/3837/10/23)

PMCPA ruled AstraZeneca breached Clause 5.5 after a contracted HCP tweeted #speakupforCOPD without declaring their association. Website disclosure was deemed sufficiently prominent;…

2023
CASE
AUTH/3835/10/23 Moderna

Moderna employee’s policy articles and X activity: lack of transparency, one public POM advert and compliance framework failings (AUTH/3835/10/23)

PMCPA found Moderna responsible for a senior employee’s policy articles and X reposts. Missing disclosure breached Clause 5.5 and high standards (5.1).…

2024
CASE
AUTH/3904/5/24 Gedeon Richter

AUTH/3904/5/24: Complainant v Gedeon Richter (Evra ad and linked e-detail pages) – No breach

Complaint alleged Evra ad and linked β€˜Benefits’/β€˜Safety & tolerability’ pages omitted full indication and key risks/contraindications. Panel found no breach of Clauses…

2024
CASE
AUTH/3899/5/24 GlaxoSmithKline

AUTH/3899/5/24: Complainant v GSK β€” COPD therapy review Joint Working classification and certification (No breach)

Complaint alleged a COPD therapy review service was misclassified as Joint Working and that software, patient leaflets and consultation summaries weren’t certified.…

2019
CASE
AUTH/3283/11/19 Bristol-Myers Squibb Pharmaceuticals

AUTH/3283/11/19 and AUTH/3284/11/19: CCG senior pharmacist v Bristol-Myers Squibb and Pfizer (Eliquis promotion and litigation comments)

Two Alliance representatives raised litigation/medico-legal consequences during a promotional meeting about Eliquis amid cost-driven switching to Lixiana. The Panel found scaremongering and…

2008
CASE
Janssen

Janssen-Cilag Lyrinel XL ad: illustration found to misrepresent study discontinuations and recommendation rates

A pharmacist challenged a Lyrinel XL ad’s β€œGets our vote” imagery. The Panel found the illustration exaggerated satisfaction by ignoring discontinuations and…

2008
CASE
AUTH/2097/2/08 Trinity-Chiesi Pharmaceuticals

AUTH/2097/2/08: Teva v Trinity-Chiesi – Clinical support service pharmacist forms (no breach)

Teva challenged two Trinity-Chiesi clinical support service pharmacist forms implying increased use of Clenil Modulite. The Panel found the complaint was too…

2008
CASE
AUTH/2148/7/08 Trinity-Chiesi Pharmaceuticals

AUTH/2148/7/08 AstraZeneca v Trinity-Chiesi: Fostair cost comparison chart (no breach)

AstraZeneca challenged Trinity-Chiesi’s Fostair cost comparison chart as incomplete and misleading versus Symbicort and Seretide. The Panel found the chart acceptable in…

2008
CASE
AUTH/2141/7/08 Sanofi ⭐ Case of the Week

AUTH/2141/7/08: Novo Nordisk v Sanofi-Aventis – Promotion of Lantus (claims on 24-hour efficacy and hypoglycaemia risk)

Complaint about Lantus promotional leavepieces and a mailer. Issues included β€œ24-hour efficacy” wording and a hypoglycaemia comparison based on pooled observational data.…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training